Clinical Trials Logo

Filter by:
NCT ID: NCT01972776 Terminated - COPD Clinical Trials

A Safety, Tolerability and Efficacy Study in COPD Patients With QBM076.

Start date: November 2013
Phase: Phase 2
Study type: Interventional

This is a 2 Part study. Part 1 is a safety and tolerability study in GOLD I-III COPD patients. Part 2 is an efficacy study in GOLD I-III COPD patients.

NCT ID: NCT01972126 Terminated - Clinical trials for Acute Myocardial Infarction

MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction

MAGNITUDE
Start date: September 2013
Phase: N/A
Study type: Observational

The MAGNetic QRS-Fragmentation in Patients with Myocardial InfarcTion and Moderately RedUceD Ejection Fraction (MAGNITUDE) study will assess in MI survivors with moderately reduced left ventricular function, whether non-invasive MFI QRS Fragmentation alone or in combination with parameters derived from a Holter recording can be used to identify a group of patients at high risk for SCD/life threatening ventricular arrhythmia.

NCT ID: NCT01969136 Terminated - Dementia Clinical Trials

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Start date: October 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.

NCT ID: NCT01969123 Terminated - Dementia Clinical Trials

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Start date: October 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.

NCT ID: NCT01964885 Terminated - Common Cold Clinical Trials

Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections

Start date: October 2013
Phase: Phase 3
Study type: Interventional

IQP-AS-105, is a food supplement derived from garlic (Allium sativum). The objective of this study is to evaluate the possibilities of clinical use of IQP-AS-105 as a preventive medicine, based on its ability to enhance the immune system responses

NCT ID: NCT01964378 Terminated - Pain Clinical Trials

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

CORAL
Start date: October 29, 2013
Phase: Phase 3
Study type: Interventional

Pain is one of the most common symptoms associated with malignant tumor. The purpose of this trial is to determine whether cebranopadol is as effective in patients with cancer related pain as morphine sulfate prolonged release (PR).

NCT ID: NCT01963650 Terminated - Clinical trials for Nervous System Diseases

Natural History Study of Children With Metachromatic Leukodystrophy

Start date: November 2, 2015
Phase:
Study type: Observational

The purpose of this study is evaluate the natural course of disease progression related to gross motor function in children with metachromatic leukodystrophy (MLD).

NCT ID: NCT01959425 Terminated - Clinical trials for Paroxysmal Atrial Fibrillation

Oral Anticoagulation Therapy Pilot Study

OAT
Start date: April 17, 2013
Phase: Phase 4
Study type: Interventional

The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.

NCT ID: NCT01958060 Terminated - Healthy Clinical Trials

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

Start date: October 2013
Phase: Phase 1
Study type: Interventional

Investigation of safety and tolerability of BI 1034020 in healthy male volunteers following intravenous (IV) infusion of subcutaneous (SC) injection of single doses and exploration of the pharmacokinetics and pharmacodynamics of BI 1034020 after single dosing and determination of the bioavailability of subcutaneous injections of BI 1034020

NCT ID: NCT01957644 Terminated - Clinical trials for Myelodysplastic Syndromes

Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

Start date: November 6, 2013
Phase: Phase 1
Study type: Interventional

To investigate the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of volasertib in combination with azacitidine in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) and not candidates for hematopoietic stem cell transplant